Genotype-Guided Selection of Antiplatelet Therapy: The Evidence Moves East

JACC Cardiovasc Interv. 2023 Apr 10;16(7):844-846. doi: 10.1016/j.jcin.2023.02.021. Epub 2023 Mar 8.

Authors

Larisa H Cavallari¹, Francesco Franchi²

Affiliations

¹ Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, Florida, USA. Electronic address: lcavallari@cop.ufl.edu.
² Department of Medicine, Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.

PMID: 36898938
DOI: 10.1016/j.jcin.2023.02.021

No abstract available

Keywords: CYP2C19 genotype; clopidogrel; percutaneous coronary intervention.

Publication types

Editorial
Comment

MeSH terms

Acute Coronary Syndrome*
Clopidogrel
Cytochrome P-450 CYP2C19 / genetics
Genotype
Humans
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors / adverse effects
Ticagrelor
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Clopidogrel
Ticagrelor
Cytochrome P-450 CYP2C19